J Cancer 2017; 8(18):3689-3696. doi:10.7150/jca.19501


Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy

Shu-juan Zhou1, Jia Wei1, Shu Su1, Fang-jun Chen1, Yu-dong Qiu2✉, Bao-rui Liu1✉

1. The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China;
2. Department of Hepatopancreatobiliary Surgery, The Affiliated Drum Tower Hospital of Medical School of Nanjing University, Nanjing, China.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Zhou Sj, Wei J, Su S, Chen Fj, Qiu Yd, Liu Br. Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy. J Cancer 2017; 8(18):3689-3696. doi:10.7150/jca.19501. Available from http://www.jcancer.org/v08p3689.htm

File import instruction


Genetic engineering has resulted in more than 50 recombinant bispecific antibody formats over the past two decades. Bispecific scFv antibodies represent a successful and promising immunotherapy platform that retargets cytotoxic T cells to tumor cells, with one scFv directed to tumor-associated antigens and the other to T cells. Based on this antibody construct, strategies for both specific tumor targeting and T cell activation are reviewed here. Three distinct types of tumor antigens are considered to optimize specificity and safety in bispecific scFv based treatment: cancer-testis antigens, neo-antigens and virus-associated antigens. In terms of T cell activation, although CD3 has been widely applied in bispecific scFvs being developed, CD28 and CD137 among co-stimulatory signals are also ideal candidates to be evaluated. Besides, LIGHT and HIV-Tat101 have drawn much attention as their potential roles in modulating antitumor responses.

Keywords: bispecific antibody, cancer-testis antigen, neoantigen, co-stimulatory signals.